Oncology · Endocrine Oncology
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Anaplastic thyroid carcinoma is the most aggressive and lethal form of thyroid cancer, typically presenting in elderly patients.
Patients present with a rapidly enlarging, hard, fixed neck mass that often causes compressive symptoms such as dysphagia, dyspnea, or hoarseness.
Physical examination reveals a rock-hard thyroid mass that is often associated with cervical lymphadenopathy and vocal cord paralysis.
The diagnosis is confirmed via fine-needle aspiration (FNA) or core needle biopsy, which demonstrates highly pleomorphic, giant cells, and spindle cells with frequent mitoses.
Anaplastic thyroid carcinoma is always classified as Stage IV by AJCC; it is Stage IVA if intrathyroidal, IVB with gross extrathyroidal/nodal spread, and IVC only when distant metastasis (M1) is present.
The prognosis is extremely poor, with a median survival of less than 6 months and a high rate of treatment resistance.
Management requires rapid BRAF V600E and molecular testing: dabrafenib plus trametinib is used for BRAF V600E-mutant unresectable/metastatic disease, while lenvatinib plus pembrolizumab is the preferred first-line systemic option for non-BRAF-mutant metastatic disease, alongside airway protection and external beam radiation.
Vignette unlocked
A 78-year-old female presents to the emergency department with a 3-week history of a rapidly enlarging neck mass. She reports significant dyspnea when lying flat and difficulty swallowing solids. On physical exam, there is a fixed, rock-hard thyroid mass measuring 6 cm that does not move with swallowing. Vocal cord paralysis is noted on laryngoscopy. A CT scan shows the mass is invading the trachea and surrounding soft tissues.
What is the most likely diagnosis?
Anaplastic thyroid carcinoma
The patient's presentation of a rapidly enlarging, fixed, rock-hard thyroid mass in an elderly patient with compressive symptoms is classic for anaplastic thyroid carcinoma, which is known for its aggressive local invasion.
Full handout
High yield triage
Etiology / Epidemiology
Rare, aggressive malignancy in elderly patients (>65) often arising from pre-existing goiter or differentiated thyroid cancer.
Clinical Manifestations
Presents as a rapidly enlarging, fixed, hard neck mass causing compressive symptoms like dyspnea and dysphagia.
Diagnosis
FNA is generally the first biopsy and is diagnostic in most cases, with core needle biopsy reserved for insufficient cellular yield and molecular testing; shows undifferentiated, pleomorphic cells with high mitotic index.
Treatment
Palliative focus; multimodal therapy (surgery, radiation, chemotherapy) is rarely curative. Airway compromise requires urgent management.
Prognosis
Extremely poor; median survival is 3–6 months with nearly 100% mortality rate.
Full handout
Epidemiology & Etiology
Represents <2% of thyroid cancers but accounts for roughly 20-50% of thyroid cancer deaths. Primarily affects patients in the 7th to 8th decade of life (mean age ~65 years). Often associated with long-standing multinodular goiter or dedifferentiation of prior papillary/follicular carcinoma.
Pertinent Anatomy
The tumor originates in the thyroid gland but rapidly invades the trachea, esophagus, and recurrent laryngeal nerve. This local invasion explains the classic presentation of hoarseness and respiratory distress.
Pathophysiology
Characterized by a complete loss of thyroid differentiation markers. Driven by high-frequency TP53 mutations and rapid cellular proliferation. The tumor exhibits aggressive local invasion and early distant hematogenous metastasis to the lungs.
Clinical Manifestations
Patients present with a rapidly enlarging, rock-hard neck mass that is fixed to surrounding structures. Acute airway obstruction is a life-threatening emergency. Patients often report dysphagia, dyspnea, and hoarseness due to nerve involvement.
Diagnosis
Diagnosis is confirmed via core needle biopsy or fine-needle aspiration showing undifferentiated, pleomorphic cells. CT neck/chest with contrast is essential to assess the extent of local invasion and identify distant metastases. Avoid delay in diagnosis as the tumor doubles in size rapidly.
Treatment
Treatment is primarily palliative due to the advanced stage at presentation. Multimodal therapy including surgical debulking, external beam radiation, and systemic chemotherapy (e.g., paclitaxel) may be attempted. Rapid BRAF V600E testing is now standard; BRAF V600E-mutant unresectable or metastatic disease is treated with dabrafenib plus trametinib; for tumors without a targetable alteration, lenvatinib plus pembrolizumab is a preferred first-line systemic option. Tracheostomy is often required for airway patency, though it carries significant morbidity.
Prognosis
The prognosis is dismal, with a median survival of 3–6 months. Most patients succumb to local airway obstruction or distant metastatic disease. Early palliative care consultation is mandatory.
Differential Diagnosis
Lymphoma: rapid growth but often associated with Hashimoto thyroiditis
Medullary Thyroid Carcinoma: elevated calcitonin levels
Papillary Thyroid Carcinoma: slower growth, psammoma bodies
Follicular Thyroid Carcinoma: hematogenous spread, requires histology for diagnosis
Subacute Thyroiditis: painful, tender gland, systemic inflammatory symptoms